AstraZeneca Acquires Pearl Therapeutics for $1,150,000,000

  • Feed Type
  • Date
    6/10/2013
  • Company Name
    Pearl Therapeutics
  • Mailing Address
    200 Saginaw Drive Redwood City, CA 94063
  • Company Description
    Pearl Therapeutics is focused on developing a pipeline of novel andsuperior products for chronic respiratory disorders, providing patientswith advanced therapeutic options in familiar and well accepted dosageforms. The company has licensed advanced particle technology from NektarTherapeutics (Nasdaq: NKTR) for developing a series of products in selectedtherapeutic fields.
  • Website
    http://www.pearltherapeutics.com
  • Transaction Type
    M&A
  • Transaction Amount
    $1,150,000,000
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Astra agreed to pay $560 million upfront for Pearl, plus up to $450 million in milestone payments if products in development progress successfully, and as much as $140 million in sales payments if the drugs meet certain sales thresholds.

By posting a comment, you agree to our terms and conditions.